Maternal serum leptin, adiponectin, resistin and monocyte chemoattractant protein-1 levels in different types of diabetes mellitus

Kapustin, Roman V.; Chepanov, Sergey V.; Babakov, Vladimir; Rogovskaya, Nadezhda Yu.; Kopteeva, Ekaterina V.; Alekseenkova, Elena N.; Arzhanova, Olga N.

doi:10.1016/j.ejogrb.2020.09.050

Cited by 14 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eotaxin in pregnancy has scarcely been studied, but has been reported as predictive of hypertensive disorders in pregnancy in women without PCOS ( 50 ). Elevated baseline levels of MCP-1 related to pregnancy complications in women with PCOS are supported by a study linking elevated levels of MCP-1 to GDM in non-PCOS women ( 51 ). However, our results of altered MCP-1 levels later in pregnancy in women with PCOS independent of GDM may indicate that increased insulin resistance without GDM affects the MCP-1 development in pregnancy ( 52 ).…”

Section: Discussionmentioning

confidence: 89%

Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome

Stokkeland

Giskeødegård²,

Ryssdal

et al. 2021

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Context Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with low-grade inflammation and increased incidence of pregnancy complications, but its influence on the maternal immune system in pregnancy is unknown. Longitudinal serum cytokine profiling is a sensitive measure of the complex immunological dynamics of pregnancy. Objective Determine the immunological dynamics of serum cytokines throughout pregnancy in women with PCOS and compare it to pregnancy in women without PCOS. Design and setting A post hoc analysis of longitudinal serum samples from two randomized, placebo-controlled multicenter studies of pregnant women with PCOS and two studies of pregnant women without PCOS. Participants Pregnant women with PCOS (n = 358) and without PCOS (n = 258, controls) provided 1752 serum samples from four time points in pregnancy (weeks 10, 19, 32, 36). Main outcome measures Maternal serum levels of 22 cytokines and C-reactive protein (CRP) at four time points in pregnancy. Results Women with PCOS showed marked immunological changes in serum cytokines throughout pregnancy. Compared to controls, women with PCOS showed higher levels of 17 cytokines and CRP at week 10 of pregnancy and a distinct cytokine development throughout pregnancy. The immunological dynamics in women with PCOS was significantly affected by maternal BMI, smoking and fetal sex. Conclusion Pregnancy in women with PCOS was associated with a strong early mobilization of inflammatory and other serum cytokines persisting throughout pregnancy, indicating a more activated immune status. These findings provide a novel basis for further study of PCOS and pregnancy complications.

show abstract

Section: Discussionmentioning

confidence: 89%

Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome

Stokkeland

Giskeødegård²,

Ryssdal

et al. 2021

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

“…In our cohort, although women with HDP had a greater BMI, HDP was associated with higher maternal leptin levels in both normal weight and obese women, in agreement with others publications [ 30 , 31 ]. In addition, we found greater levels of MCP-1 in diabetic women and even higher levels in diabetic women who developed HDP, suggesting a role in the activation of chronic inflammation in GDM [ 33 , 34 ]. As others have found, we were not able to detect many other proinflammatory cytokines associated with preeclampsia, such as resistin [ 25 ] or TNFα [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

Angiogenic Imbalance and Inflammatory Biomarkers in the Prediction of Hypertension as Well as Obstetric and Perinatal Complications in Women with Gestational Diabetes Mellitus

Lara-Barea

Sánchez-Lechuga

Campos‐Caro

et al. 2022

JCM

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) increases the risk of hypertensive disorders of pregnancy (HDP). We aimed to analyze the altered inflammatory markers and angiogenic factors among women with GDM to identify pregnant women at higher risk of developing HDP. Methods: This was a prospective study of 149 women without hypertension diagnosed in the third trimester with GDM. Inflammatory markers and angiogenic factors were measured at 28–32 weeks of pregnancy. Obstetric and perinatal outcomes were evaluated. Results: More than eight percent of the women developed HDP. Higher levels of the soluble fms-like tyrosine kinase-1/placental growth factor (sFlt-1/PIGF) ratio (4.9 ± 2.6 versus 2.3 ± 1.3, respectively; p < 0.001) and leptin (10.9 ± 0.8 versus 10.08 ± 1.1, respectively; p = 0.038), as well as lower levels of adiponectin (10.5 ± 1.3 versus 12.9 ± 2.7, respectively; p = 0.031), were seen in women who developed HDP versus normotensive women with GDM. A multivariable logistic regression analysis showed that adiponectin had a protective effect with 0.45-fold odds (0.23–0.83; p = 0.012), and that the sFlt-1/PIGF ratio was associated with 2.70-fold odds of developing HDP (CI 95%: 1.24–5.86; p = 0.012). Conclusion: An increase in angiogenic imbalance in the sFlt-1/PIGF ratio in women with GDM was detected and may be an indicator of developing HDP in addition to any subsequent obstetric and perinatal complications.

show abstract

“…It is notable in this regard that IGF-1 markedly upregulates GLUT-1 expression in the basal membrane of the syncytium and stimulates transepithelial glucose transport 15 . Moreover, in relation to PGDM mothers, increased resistin levels present at the beginning of pregnancy constitute a factor with the documented stimulating effect on GLUT-1 expression in the placenta, being also positively correlated with HbA1c concentration and FBW 14,18 .…”

Section: Discussionmentioning

confidence: 99%

“…According to the Pedersen hypothesis, diabetes in the mother and the associated hyperglycemia in pregnancy leads to the increased flow of glucose to the fetus, triggering a cascade of metabolic changes that lead to fetal hyperinsulinemia and, as a result, excessive fetal growth 11 . Apart from hyperglycemia and hyperinsulinemia, the results of metabolic derangement in diabetic pregnancy include quantitative changes in the concentration of certain hormones (insulin), growth factors (insulin-like growth factor [IGF] 1 and 2) and cytokines (resistin) involved in the processes of cell growth regulation [12][13][14] . The results of the recent in vitro studies indicate that one of the mechanisms of action of the abovementioned factors might be the stimulating effect on GLUT protein expression in different placental compartments [15][16][17][18] .…”

Section: Introductionmentioning

confidence: 99%

Placental expression of glucose transporters GLUT‐1, GLUT‐3, GLUT‐8 and GLUT‐12 in pregnancies complicated by gestational and type 1 diabetes mellitus

Stanirowski

Szukiewicz

Majewska

et al. 2021

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction: The aim of the present study was to evaluate the placental expression of glucose transporters GLUT-1, GLUT-3, GLUT-8 and GLUT-12 in term pregnancies complicated by well-controlled gestational (GDM) and type 1 pregestational diabetes mellitus (PGDM). Materials and Methods: A total of 103 placental samples were obtained from patients diagnosed with GDM (n = 60), PGDM (n = 20) and a non-diabetic control group (n = 23). Computer-assisted quantitative morphometry of stained placental sections was performed to determine the expression of selected GLUT proteins. Results: Immunohistochemical techniques used for the identification of GLUT-1, GLUT-3, GLUT-8 and GLUT-12 revealed the presence of all glucose transporters in the placental tissue. Morphometric evaluation performed for the vascular density-matched placental samples demonstrated a significant increase in the expression of GLUT-1 protein in patients with PGDM as compared to GDM and control groups (P < 0.05). With regard to the expression of the other GLUT isoforms, no statistically significant differences were observed between patients from the diabetic and control populations. Positive correlations between fetal birthweight and the expression of GLUT-1 protein in the PGDM group (rho = 0.463, P < 0.05) and GLUT-12 in the control group (rho = 0.481, P < 0.05) were noted. Conclusions: In term pregnancies complicated by well-controlled GDM/PGDM, expression of transporters GLUT-3, GLUT-8 and GLUT-12 in the placenta remains unaffected. Increased expression of GLUT-1 among women with type 1 PGDM might contribute to a higher rate of macrosomic fetuses in this population.

show abstract

Maternal serum leptin, adiponectin, resistin and monocyte chemoattractant protein-1 levels in different types of diabetes mellitus

Cited by 14 publications

References 25 publications

Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome

Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome

Angiogenic Imbalance and Inflammatory Biomarkers in the Prediction of Hypertension as Well as Obstetric and Perinatal Complications in Women with Gestational Diabetes Mellitus

Placental expression of glucose transporters GLUT‐1, GLUT‐3, GLUT‐8 and GLUT‐12 in pregnancies complicated by gestational and type 1 diabetes mellitus

Contact Info

Product

Resources

About